Uterine papillary serous carcinoma: A review

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 6, 2007, Pages 809-816

  Gehrig, Paola A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Endometrial adenocarcinoma; Radiation therapy; Surgical staging; Uterine papillary serous carcinoma

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; PLATINUM COMPLEX; TAMOXIFEN; TOPOTECAN; TRASTUZUMAB; TUMOR MARKER;

ADVANCED CANCER; BLOOD TOXICITY; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; ENDOMETRIUM CANCER; GENE MUTATION; HUMAN; MOLECULAR BIOLOGY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATHOGENESIS; POSTOPERATIVE CARE; PREOPERATIVE CARE; REVIEW; RISK FACTOR; UTERUS BIOPSY; UTERUS CARCINOMA; UTERUS PAPILLARY SEROUS CARCINOMA; CYSTADENOCARCINOMA; DISEASE FREE SURVIVAL; FEMALE; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; UTERUS CANCER;

COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, PAPILLARY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM STAGING; UTERINE NEOPLASMS;

EID: 34247895721     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.6.809     Document Type: Review

References (55)

1. CA A Cancer Journal for Clinicians (2005) 55(1):10-30.
2. DUNTON CJ, BALSARA G, MCFARLAND M et al.: Uterine papillary serous carcinoma: a review. Obstet. Gynecol. Surv. (1991) 46:97-102.
3. KATO DT, FERRY JA, GOODMAN A et al.: Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol. Oncol. (1995) 59:384-389.
4. ROSENBERG P, BLOM R, HOGBERG T et al.: Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma. Gynecol. Oncol. (1993) 51:311-315.
5. CARCANGUI ML, CHAMBERS JT: Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion and concomitant ovarian carcinoma. Gynecol. Oncol. (1992) 47:298-305.
6. ROSENBERG P, BOERYD B, SIMONSEN E: A new aggressive treatment approach to high-grade endometrial cancer of possible benefit to patients with stage I uterine papillary cancer. Gynecol. Oncol. (1993) 48:32-37.
7. HENDRICKSON M, ROSS J, EIFEL P et al.: Uterine papillary serous carcinoma - a highly malignant form of endometrial adenocarcinoma. Am. J. Surg. Path. (1982) 6:93-108.
8. HUH W, POWELL M, LEATH CA et al.: Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy. Gynecol. Oncol. (2003) 91:470-475.
9. SLOMOVITZ BM, BURKE TW, EIFEL PJ et al.: Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol. Oncol. (2003) 91:463-469.
10. CARCANGUI ML, TAN LK, CHAMBERS JT: Stage IA uterine serous carcinoma: a study of 13 cases. Am. J. Surg. Pathol. (1997) 21:1507-1514.
11. BRISTOW RE, ASRARI F, TRIMBLE EL, et al. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (stage I - III) disease. Gynecol. Oncol. (2001) 81:279-286.
12. BANCHER-TODESCA D, GITSCH G, WILLIAMS KE et al.: p53 protein overexpression: a strong prognostic factor in uterine papillary serous carcinoma. Gynecol. Oncol. (1998) 71:59-63.
13. CHAN JK, LOIZZI V, YOUSSEF M et al.: Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol. Oncol. (2003) 90:181-185.
14. RISINGER JL, HAYES K, MAXWELL GL et al.: PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin. Cancer. Res. (1998) 4:3005-3010.
15. MAXWELL GL, RISINGER JL, ALVAREZ AA et al.: Microsatellite instability is associated with favorable survival in endometrial carcinomas. Obstet. Gynecol. (2001) 97:417-422.
16. TASHIRO H, LAX SF, GAUDIN PB et al.: Microsatellite instability is uncommon in uterine serous carcinoma. Am. J. Pathol. (1997) 150:75-79.
17. SLOMOVITZ BM, BROADDUS RR, BURKE TW et al.: Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J. Clin. Oncol. (2004) 22:3126-3132.
18. ARLT MF, HERZOG TJ, MUTCH DG et al.: Frequent deletion of chromosome 1p sequences in an aggressive subtype of endometrial cancer. Hum. Mol. Genet. (1996) 5:1017-1021.
19. MAXWELL GL, CHANDRAMOULI GVR, DAINTY L et al.: Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveal distinct gene expression profiles associated with different histologic types of uterine cancer. Clin. Cancer. Res. (2005) 11:4056-4066.
20. SHERMAN ME, BITTERMAN P, ROSENSHEIN NB et al.: Uterine serous carcinoma: a morphologically diverse neoplasm with unifying clinicopathologic features. Am. J. Surg. Path. (1992) 16:600-610.
21. ZHENG E, SCHWARZ PE: Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management. Gynecol. Oncol. (2005) 96:579-582.
22. GOFF BA, KATO D, SCHMIDT RA et al.: Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol. Oncol. (1994) 54:264-268.
23. GEHRIG PA, GROBEN PA, FOWLER WC: Noninvasive papillary serous carcinoma of the endometrium. Obstet. Gynecol. (2001) 97:153-157.
24. KUPRYJANCZYK J, THOR AD, BEAUCHAMP R et al.: Ovarian, peritoneal and endometrial serous carcinoma: clonal origin of multifocal disease. Mod. Pathol. (1996) 9:166-173.
25. BORUTA DM, GEHRIG PA, GROBEN PA et al.: Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer (2004) 101:2214-2221.
26. GOSHEN R, CHU W, ELIT L et al.: Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol. Oncol. (2000) 79:477-481.
27. LAVIE O, HORNREICH G, ARIE AB et al.: BRCA1 germline mutations in women with uterine papillary serous carcinoma. Obstet. Gynecol. (2000) 96:28-32.
28. MAGRIPLES U, NAFTOLIN F, SCHWARTZ PE et al.: High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J. Clin. Oncol. (1993) 11:485-490.
29. GEHRIG PA, BAE-JUMP VL, BOGGESS JF et al.: Association between uterine serous carcinoma and breast cancer. Gynecol. Oncol. (2004) 94:208-211.
30. GEISLER JP, SOROSKY JI, DUONG HL et al.: Papillary serous carcinoma of the uterus: increased risk of subsequent of concurrent development of breast carcinoma. Gynecol. Oncol. (2001) 83:501-503.
31. GRICE J, EK M, GREER B et al.: Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol. Oncol. (1998) 69:69-73.
32. GEISLER JP, GEISLER HE, MELTON ME et al.: What staging surgery should be performed on patients with uterine papillary serous carcinoma? Gynecol. Oncol. (1999) 74:465-467.
33. GEHRIG PA, VAN LE L, FOWLER WJ: The role of omentectomy during the surgical staging of uterine serous cancer. Int. J. Gynecol. Cancer (2003) 13:212-215.
34. MOLLER KA, GEHRIG PA, VAN LE L: The role of optimal debulking in advanced stage serous carcinoma of the uterus. Gynecol. Oncol. (2004) 94:170-174.
35. BRISTOW RE, DUSKA LR, MONTZ FJ: The role of cytoreducrive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol. Oncol. (2001) 81:92-99.
36. ABRAMOVICH D, MARKMAN M, KENNEDY A et al.: Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma. J. Cancer. Res. Clin. Oncol. (1999) 125:697-698.
37. PRICE FV, CHAMBERS SK, CARCANGUI ML et al.: CA-125 may not reflect disease status in patients with uterine serous carcinoma. Cancer (1998) 82:1720-1725.
38. MEHTA N, YAMADA SD, ROTMENSCH J et al.: Outcome and pattern of failure in pathologic stage I - II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. (2003) 57:1004-1009.
39. LIM P, KUSHI AA, GILKS B et al.: Early stage uterine papillary serous carcinoma of the endometrium: effect of adjuvant whole abdominal radiotherapy and pathologic parameters of outcome. Cancer (2001) 91:752-757.
40. SUTTON G, BUNDY B, AXELROD J et al.: Whole abdominal radiotherapy in stage I-II papillary serous or clear cell cancers of the uterus (A GOG Study). Gyncol. Oncol. (2002) 84:479-536 (SGO abstr 205).
41. 32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a Phase II Hoosier Oncology Group (HOG 97-01) study. Gynecol. Oncol. (2005) 96:818-823.
42. BURKE T, GERSHENSON D, MORRIS M, STRINGER A, LEVENBACK C, TORTOLERO-LUNA G, BAKER V: Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide chemotherapy in women with high-risk endometrial cancer. Gynecol. Oncol. (1994) 55:47-50.
43. LEVENBACK C, BURKE T, SILVA E, MORRIS M et al.: Uterine papillary serous carcinoma treated with cisplatin, doxorubicin, and cyclophosphamide. Gynecol. Oncol. (1992) 46:317-321.
44. KELLY MG, O'MALLEY DM, HUI P et al.: Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol. Oncol. (2005) 98:353-359.
45. ZANOTTI KM, BELINSON JL, KENNEDY AW et al.: The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol. Oncol. (1999) 74:272-277.
46. RAMONDETTA L, BURKE TW, LEVENBACK C et al.: Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol. Oncol. (2001) 82:156-161.
47. GEHRIG PA, MORRIS DR, VAN LE L: Uterine serous carcinoma: a comparison of therapy for advanced-stage disease. Int. J. Gynecol. Cancer (2005) 14:515-520.
48. RANDALL ME, BRUNETTO G, MUSS H et al.: Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: a randomized Phase III trial of the Gynecologic Oncology Group. J. Clin. Oncol. (2006) 24:36-44.
49. GEHRIG PA, BORUTA DM, MOLLER KA et al.: Multiagent chemotherapy and radiotherapy for the treatment of advanced endometrial carcinoma. Gynecol. Oncol. (2005) 96:973.
50. LOW JSH, WONG EH, TAN HSK et al.: Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma. Gynecol. Oncol. (2005) 97:171-177.
51. CHAMBERS JT, RUTHERFORD TJ, SCHWARTZ PE et al.: A pilot study of topotecan in the treatment of serous carcinoma of the uterus. Int. J. Gynecol. Cancer (2003) 13:216-222.
52. CHAN JK, CHEUNG MK, HUH WK et al.: Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer (2006) 15:1823-1830.
53. SLOMOVITZ BM, BROADDUS RR, BURKE TW et al.: Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J. Clin. Oncol. (2004) 22:3126-3132.
54. VILLELLA JA, COHEN S, SMITH DH et al.: HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int. J. Gynecol. Cancer (2006) 16:1897-902.
55. GOFF BA: Uterine papillary serous carcinoma: what have we learned over the past quarter century? Gynecol. Oncol. (2005) 98:341-343.